Evotec and Odyssey collaborate on AI-enabled R&D
Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and…
All articles by Srivani Venna
Srivani Venna
-
-
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases. These…
-
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies
Telix and Regeneron Pharmaceuticals have entered a partnership worth up to $4.3bn for the development and commercialisation of new radiopharmaceutical…
-
FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application…
-
Atombeat and BioDuro link for peptide drug discovery platform
Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery. The…
-
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi
Arrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the rights to develop and commercialise…
-
Sanofi’s Sarclisa gains EC approval for multiple myeloma treatment
The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, lenalidomide and dexamethasone…
-
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
-
Swissmedic approves Novartis’ malaria medicine for babies
The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for…
-
GSK acquires efimosfermin alfa from Boston Pharma for $2bn
GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in…